for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ESSA Pharma Inc

EPIX.OQ

Latest Trade

27.23USD

Change

0.33(+1.23%)

Volume

27,760

Today's Range

26.32

 - 

27.41

52 Week Range

5.15

 - 

35.45

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
26.90
Open
26.90
Volume
27,760
3M AVG Volume
4.88
Today's High
27.41
Today's Low
26.32
52 Week High
35.45
52 Week Low
5.15
Shares Out (MIL)
40.46
Market Cap (MIL)
1,088.26
Forward P/E
-24.96
Dividend (Yield %)
--

Next Event

Q3 2021 ESSA Pharma Inc Earnings Release

Latest Developments

More

Essa Pharma Reports Q2 Loss Per Share $0.36

Essa Pharma Announces Clinical Collaboration With Astellas

Essa Pharma Announces Pricing Of Public Offering Of Common Shares

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ESSA Pharma Inc

ESSA Pharma, Inc. is a Canada-based pharmaceutical company. The Company is focused on developing therapies for the treatment of castration-resistant prostate cancer (CRPC). It is developing EPI-7386 for the treatment of metastatic CRPC (mCRPC). It is also developing EPI-7386 combination therapy for mCRPC. In addition to this, the Company's pipeline also includes antien for triple negative androgen receptor (AR+) breast cancer. Its aniten compounds bind to the N-terminal domain of the androgen receptor (AR), inhibiting AR driven transcription and the AR signaling pathway in a manner which bypasses the drug resistance mechanisms associated with current anti-androgens.

Industry

Biotechnology & Drugs

Contact Info

999 Broadway W Suite 720

VANCOUVER, BC

V5Z 1K5

Canada

+1.778.3310962

https://www.essapharma.com/

Executive Leadership

Richard M. Glickman

Non-Executive Independent Chairman of the Board

David Ross Parkinson

President, Chief Executive Officer, Director

David Sidney Wood

Chief Financial Officer

Peter Virsik

Chief Operating Officer, Executive Vice President

Alessandra Cesano

Chief Medical Officer

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-2.550

2019

-1.510

2020

-1.040

2021(E)

-1.120
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
5.29
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-23.45
Return on Equity (TTM)
-23.01

Latest News

Latest News

BRIEF-Essa Pharma Presents Potential Of Epi-7386 At American Association For Cancer Research Meet

* ESSA PHARMA PRESENTS THERAPEUTIC POTENTIAL OF EPI-7386 AT THE 2020 AMERICAN ASSOCIATION FOR CANCER RESEARCH VIRTUAL ANNUAL MEETING II Source text for Eikon: Further company coverage:

BRIEF-Essa Pharma Presents Therapeutic Potential Of EPI-7386 At Virtual American Urological Association Annual Meeting

* ESSA PHARMA PRESENTS THERAPEUTIC POTENTIAL OF EPI-7386 AT 2020 VIRTUAL AMERICAN UROLOGICAL ASSOCIATION (AUA) ANNUAL MEETING Source text for Eikon: Further company coverage:

BRIEF-Essa Pharma Reports Quarterly Net Loss Of $0.45 Per Common Share

* ESSA PHARMA PROVIDES CORPORATE UPDATE AND REPORTS FINANCIAL RESULTS FOR FISCAL SECOND QUARTER ENDED MARCH 31, 2020

BRIEF-Essa Pharma Says May Offer And Sell Common Of Up To $35 Mln From Time To Time

* ESSA PHARMA INC - MAY OFFER AND SELL COMMON OF UP TO $35 MILLION FROM TIME TO TIME - SEC FILING

BRIEF-Essa Pharma Submits Ind For Epi-7386 For Prostate Cancer And Provides Business Update

* ESSA PHARMA SUBMITS IND FOR EPI-7386 FOR PROSTATE CANCER AND PROVIDES BUSINESS UPDATE

BRIEF-Essa Pharma Provides Reports Financial Results For Q1 Ended December 31, 2019

* ESSA PHARMA PROVIDES CORPORATE UPDATE AND REPORTS FINANCIAL RESULTS FOR FISCAL FIRST QUARTER ENDED DECEMBER 31, 2019

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up